In our study, both the QUE and TET groups showed a significant downregulation trend in the TGFB1 gene, suggesting that the therapeutic effects of QUE and TET on RCC may be related to the TGF-β signaling pathway.[46]. The gene discussed is TGFB1; the disease is renal cell carcinoma.